Login or sign up
For business

Perseid Therapeutics

3.9· 9 reviews
Average ratingAverage
3.9/ 5

Based on 9 reviews

522%
444%
333%
20%
10%
Ask AI

Ask AI about Perseid Therapeutics

Generated with AI from 9 reviews on Trustburn

AI-generated from reviews on this page. Verify anything important with the company directly.

Debbie Ext
Reviews 1

Perseid Therapeutics is a great company to work with. The company provides an excellent working environment and values its employees. The management team is supportive and encourages growth. I would highly recommend this company to anyone looking for a rewarding career.

James McDonald
Reviews 1

I had a wonderful experience collaborating with the team at perseidtherapeutics.com. They have a great understanding of the industry and provide valuable insights. I appreciate their professionalism and timely delivery of results. It was a pleasure working with them.

Edmar Soriano
Reviews 1

👍 Perseid Therapeutics website is top-notch! They offer a wide range of services and their team is highly skilled. Their dedication towards customer satisfaction is commendable. The platform is user-friendly and the customer support team is responsive. Highly recommended! 👍

Jessica Davidoff
Reviews 1

My experience with Perseid Therapeutics has been nothing short of amazing. The team is knowledgeable, professional, and dedicated. They go above and beyond to deliver exceptional results. It's a pleasure working with them and I highly recommend their services.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About Perseid Therapeutics

Perseid Therapeutics LLC was founded in September 2009 as a joint venture between Maxygen, Inc. and Astellas Pharma Inc. to co-develop Maxygen's technology assets in protein pharmaceuticals, including MAXY-4, a next-generation CTLA4-Ig. Under the terms of the agreement, Astellas received worldwide rights to commercialize MAXY-4 for autoimmune disease and transplantation.